Enhanced cytolytic activity of tumor infiltrating lymphocytes (TILs) derived from an ICAM-1 transfected tumor in a murine model

Journal of Surgical Research

Volumn 75, Issue 1, 1998, Pages 49-53

  Lefor, Alan T ^a   Fabian, Dagmar F ^b  

^a KMC Department of Surgery   (United States)

^b NONE

Author keywords

ICAM 1; Murine tumors; Tumor infiltrating lymphocytes

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL STRAIN K 562; CONTROLLED STUDY; FEMALE; FIBROSARCOMA; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0032519371     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1997.5242     Document Type: Article

References (21)

1. Naganuma H., Kiessling R., Patarroyo M. Increased susceptibility of IFNγ treated neuroblastoma cells to lysis by lymphokine activated killer cells: Participation of ICAM-1 induction on target cells. Int. J. Cancer. 47:1991;527.
2. Sartor W. M., Kyprianou N., Fabian D. F., Lefor A. T. Enhanced expression of ICAM-1 in a murine fibrosarcoma reduces tumor growth rate. J. Surg Res. 59:1995;66.
3. Quillet-Mary A., Cavarec L., Kermarrec N. Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3, and ICAM-1 are not the major adhesion ligands on targets. Int. J. Cancer. 47:1991;473.
4. Burno D. K., Kyprianou N., Sartor W. M. Transfection of a murine fibrosarcoma with intercellular adhesion molecule-1 enhances the response to adoptive immunotherapy. Surgery. 118:1995;237.
5. Turner J., Rhee C., Fabian D. F., Lefor A. T. Increased cellular adhesion in vivo. J. Surg. Onc. 66:1997;39.
6. Van Seventer G. A., Shimizu Y., Horgan K. J., Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T-cell receptor mediated activation of resting T cells. J. Immunol. 144:1990;4579.
7. Pandolfi F., Trentin L., Boyle L. A. Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumor-infiltrating lymphocytes. Cancer. 69:1992;1165.
8. Miller A. R., McBride W. H., Hunt K., Economou J. S. Cytokine-mediated gene therapy for cancer. Ann Surg. Oncol. 1:1994;435.
9. Lefor A. T., Steinberg S. M., Wiebke E. A. Analysis of chromium-51 release assay data using personal computer spreadsheet software. Comp. Biomed Res. 21:1988;268.
10. Breen E., Steele G., Mercurio A. M. Role of the E-Cadherin/α-Catenin complex in modulating cell-cell and cell-matrix adhesive properties of invasive colon carcinoma cells. Ann. Surg. Oncol. 2:1995;378.
11. Koyama S., Ebihara T., Fukao K. Expression of intercellular adhesion molecule 1 (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma. J. Cancer Res. Clin. Oncol. 18:1992;609.
12. Geehan D. M., Fabian D. F., Lefor A. T. Local hyperthermia abrogates the anti-immunotherapeutic effect of Interleukin-8. J. Surg. Onc. 56:1994;102.
13. Lefor A. T., Foster C. E., Sartor W. Hyperthermia increases intercellular adhesion molecule-1 expression and lymphocyte adhesion to endothelial cells. Surgery. 116:1994;214.
14. Burno D. K., Fabian D. F., Lefor A. T. ICAM-1 increases in vivo adhesion and cytotoxicity in a murine fibrosarcoma. J. Surg Res. 60:1996;398.
15. Rosenberg S. A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 233:1986;1318.
16. Burger U. L., Chang M. P., Goedegebuure P. S., Eberlein T. J. Recruitment of CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer. Surgery. 117:1995;325.
17. Becker J. C., Dummer R., Hartmann A. A. Shedding of ICAM-1 from human melanoma cell lines induced by IFNg and tumor necrosis factor-a. J. Immunol. 147:1991;4398.
18. Becker J. C., Termeer C., Schmidt R. E., Brocker E. B. Soluble intercellular adhesion molecule 1 inhibits MHC-restricted specific T-cell/tumor interactions. J. Immunol. 151:1993;7224.
19. Freeman S. M., Abboud C. N., Whartenby K. A. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53:1993;5274.
20. Stötter H., Wiebke E. A., Tomita S. Cytokines alter target cell susceptibility to lysis II. Evaluation of tumor infiltrating lymphocytes. J. Immunol. 142:1989;1767.
21. Hosch S. B., Meyer A. J., Schneider C. Expression and prognostic significance of HLA Class I, ICAM-1 and tumor infiltrating lymphocytes in esophageal cancer. J. Gastrointest. Surg. 1:1997;316.